EMA Authorised: Cerdelga (Eliglustat (tartrate)) — Sanofi B.V.

View source ↗

Summary

The European Medicines Agency authorised Cerdelga (eliglustat tartrate) for Gaucher disease, with orphan medicine designation; decision date 16 May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• Cerdelga (Eliglustat)

Snippet

Status: Authorised. Therapeutic area: Gaucher Disease. MAH: Sanofi B.V.. Decision date: 16/05/2025. Orphan medicine